Literature DB >> 10777473

New therapeutic strategies for lung cancer: biology and molecular biology come of age.

P A Bunn1, A Soriano, G Johnson, L Heasley.   

Abstract

The current understanding of the biology and molecular biology of lung cancer pathogenesis and progression is reviewed. Awareness of the influence of growth factors, oncogenes, and tumor suppressor genes as well as signal transduction and angiogenesis pathways on the natural history of cancer cells has led to attempts to develop new therapeutic strategies directed at interrupting tumor cell growth. Treatments utilizing monoclonal antibodies, matrix metalloproteinase inhibitors, and gene transfer and alteration are currently being investigated. The rationale and effectiveness of these treatments in early trials are explored, and recommendations for future directions in cell biology research are presented. Interest in the biology and molecular biology of tumor cells has led to some important findings that may provide opportunities for new treatments. Several of these new directions for anticancer therapy are already being examined in phase I clinical trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777473     DOI: 10.1378/chest.117.4_suppl_1.163s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  A thioredoxin reductase 1 inhibitor pyrano [3,2-a] phenazine inhibits A549 cells proliferation and migration through the induction of reactive oxygen species production.

Authors:  Qifan Ding; Hengyu Wang; Ying Wang; Yuanyuan Lu
Journal:  Mol Biol Rep       Date:  2022-07-02       Impact factor: 2.742

2.  Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice.

Authors:  Preeti Roy; Nidhi Nigam; Madhulika Singh; Jasmine George; Smita Srivastava; Hasnain Naqvi; Yogeshwer Shukla
Journal:  Invest New Drugs       Date:  2009-06-11       Impact factor: 3.850

3.  EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.

Authors:  Haris Vikis; Mitsuo Sato; Michael James; Daolong Wang; Yian Wang; Min Wang; Dongmei Jia; Yan Liu; Joan E Bailey-Wilson; Christopher I Amos; Susan M Pinney; Gloria M Petersen; Mariza de Andrade; Ping Yang; Jonathan S Wiest; Pamela R Fain; Ann G Schwartz; Adi Gazdar; Colette Gaba; Henry Rothschild; Diptasri Mandal; Elena Kupert; Daniela Seminara; Avinash Viswanathan; Ramaswamy Govindan; John Minna; Marshall W Anderson; Ming You
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.